Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus mFOLFOX6 versus placebo plus mFOLFOX6 for unresectable advanced or recurrent small bowel cancer
jRCT2031210656Phase 2Completed
- Sponsor
- National Hospital Organization
- Start
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bevacizumab, oxaliplatin, fluorouracil and folinic acid in small bowel adenocarcinoma (SBA) (2 arms), sponsored by National Hospital Organization. Primary endpoint: Progression-free survival. Started May 2022; status: completed.
02
Drugs
bevacizumaboxaliplatinfluorouracilfolinic acid
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on jRCT2031210656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210656.